Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Drug-Drug Interactions Between Antiretrovirals and Carbamazepine/Oxcarbazepine: A Real-Life Investigation.

Cattaneo D, Baldelli S, Cozzi V, Fusi M, Atzori C, Micheli V, Filice C, Gervasoni C.

Ther Drug Monit. 2019 Nov 15. doi: 10.1097/FTD.0000000000000715. [Epub ahead of print]

PMID:
31743292
2.

Impact of Therapeutic Drug Monitoring of Antiretroviral Drugs in Routine Clinical Management of People Living With HIV: A Narrative Review.

Cattaneo D, Baldelli S, Cozzi V, Clementi E, Marriott DJE, Gervasoni C.

Ther Drug Monit. 2020 Feb;42(1):64-74. doi: 10.1097/FTD.0000000000000684.

PMID:
31393332
3.

Unexpected analytical interference in isavuconazole UV determination in a child in therapy with lumacaftor/ivacaftor for cystic fibrosis.

Baldelli S, Fusi M, Cozzi V, Clementi E, Faelli NML, Russo M, Colombo C, Cattaneo D.

Clin Chem Lab Med. 2019 Oct 25;57(11):e274-e278. doi: 10.1515/cclm-2019-0192. No abstract available.

PMID:
31141479
4.

Assessment of Antiepileptic Drug Concentrations in HIV-Infected versus HIV-Negative Patients: A Retrospective Analysis.

Cattaneo D, Baldelli S, Giacomelli A, Minisci D, Meraviglia P, Astuti N, Fusi M, Cozzi V, Clementi E, Galli M, Gervasoni C.

Clin Pharmacokinet. 2019 Oct;58(10):1345-1350. doi: 10.1007/s40262-019-00752-6.

PMID:
30945117
5.

Intrathecal nusinersen treatment for SMA in a dedicated neuromuscular clinic: an example of multidisciplinary and integrated care.

Sansone VA, Albamonte E, Salmin F, Casiraghi J, Pirola A, Bettinelli M, Rao F, Mancini L, Tovaglieri N, Fedeli F, Stoia P, Heinen M, Cozzi V, Carraro E, Lunetta C, Di Bari A, Mercuri E; Italian EAP working group.

Neurol Sci. 2019 Feb;40(2):327-332. doi: 10.1007/s10072-018-3622-9. Epub 2018 Nov 15.

PMID:
30430317
6.

Clinical and genetic determinants of nevirapine plasma trough concentration.

Giacomelli A, Rusconi S, Falvella FS, Oreni ML, Cattaneo D, Cozzi V, Renisi G, Monge E, Cheli S, Clementi E, Riva A, Galli M, Ridolfo AL.

SAGE Open Med. 2018 Jun 5;6:2050312118780861. doi: 10.1177/2050312118780861. eCollection 2018.

7.

Development and Validation of a Chromatographic Ultraviolet Method for the Quantification of Isavuconazole in Human Plasma Samples.

Cozzi V, Baldelli S, Castoldi S, Clementi E, Cattaneo D.

Ther Drug Monit. 2018 Aug;40(4):512-514. doi: 10.1097/FTD.0000000000000523. No abstract available.

PMID:
29750740
8.

High isavuconazole plasma levels in a patient with possible invasive pulmonary aspergillosis and cirrhosis.

Arsiè E, Piconi S, Iavarone M, Cozzi V, Lampertico P, Cattaneo D.

Eur J Clin Pharmacol. 2018 Aug;74(8):1089-1090. doi: 10.1007/s00228-018-2462-0. Epub 2018 Apr 18. No abstract available.

PMID:
29666903
9.

Comparison of the ARK Immunoassay With High-Performance Liquid Chromatography With Ultraviolet Detection for Therapeutic Drug Monitoring of Linezolid.

Castoldi S, Cozzi V, Baldelli S, Fucile S, Clementi E, Cattaneo D.

Ther Drug Monit. 2018 Feb;40(1):140-143. doi: 10.1097/FTD.0000000000000473.

PMID:
29324625
10.

Comparison of the Arktm Immunoassay With Hplc-Uv for Therapeutic Drug Monitoring of Linezolid.

Castoldi S, Cozzi V, Baldelli S, Fucile S, Clementi E, Cattaneo D.

Ther Drug Monit. 2017 Dec 4. doi: 10.1097/FTD.0000000000000473. [Epub ahead of print]

PMID:
29206807
11.

Is it time to revise linezolid dose in elderly patients?

Tinelli M, Gervasoni C, Piazza M, Terzi R, Cozzi V, Maffezzini E, Cerri C, Castoldi S, Baldelli S, Cattaneo D.

Eur J Clin Pharmacol. 2017 Oct;73(10):1335-1336. doi: 10.1007/s00228-017-2303-6. Epub 2017 Jul 15. No abstract available.

PMID:
28712044
12.

Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors.

Falvella FS, Ricci E, Cheli S, Resnati C, Cozzi V, Cattaneo D, Gervasoni C, Clementi E, Galli M, Riva A.

Drug Metab Pers Ther. 2017 May 24;32(2):115-117. doi: 10.1515/dmpt-2017-0006. No abstract available.

PMID:
28599374
13.

Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference.

Gervasoni C, Riva A, Cozzi V, Capetti A, Rizzardini G, Clementi E, Cattaneo D.

J Antimicrob Chemother. 2017 Jun 1;72(6):1842-1844. doi: 10.1093/jac/dkx055. No abstract available.

PMID:
28333266
14.

Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?

Cattaneo D, Minisci D, Cozzi V, Riva A, Meraviglia P, Clementi E, Galli M, Gervasoni C.

Antivir Ther. 2017;22(4):353-356. doi: 10.3851/IMP3119. Epub 2016 Dec 23.

PMID:
28008867
15.

Development of an HPLC-UV assay method for the simultaneous quantification of nine antiretroviral agents in the plasma of HIV-infected patients.

Charbe N, Baldelli S, Cozzi V, Castoldi S, Cattaneo D, Clementi E.

J Pharm Anal. 2016 Dec;6(6):396-403. doi: 10.1016/j.jpha.2016.05.008. Epub 2016 Jun 14.

16.

Therapeutic drug management of linezolid: a missed opportunity for clinicians?

Cattaneo D, Gervasoni C, Cozzi V, Castoldi S, Baldelli S, Clementi E.

Int J Antimicrob Agents. 2016 Dec;48(6):728-731. doi: 10.1016/j.ijantimicag.2016.08.023. Epub 2016 Oct 12.

PMID:
27769709
17.

Development and Validation of a Chromatographic Ultraviolet Method for the Simultaneous Quantification of Dolutegravir and Rilpivirine in Human Plasma.

Cozzi V, Charbe N, Baldelli S, Castoldi S, Atzori C, Cattaneo D, Clementi E.

Ther Drug Monit. 2016 Jun;38(3):407-13. doi: 10.1097/FTD.0000000000000290.

PMID:
26885814
18.

Is it time to revise linezolid doses in peritoneal dialysis patients? A case series.

Gervasoni C, Bergia R, Cozzi V, Clementi E, Cattaneo D.

J Antimicrob Chemother. 2015 Oct;70(10):2918-20. doi: 10.1093/jac/dkv184. Epub 2015 Jul 3. No abstract available.

PMID:
26142409
19.

Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?

Gervasoni C, Meraviglia P, Minisci D, Ferraris L, Riva A, Landonio S, Cozzi V, Charbe N, Molinari L, Rizzardini G, Clementi E, Galli M, Cattaneo D.

PLoS One. 2015 Apr 15;10(4):e0123670. doi: 10.1371/journal.pone.0123670. eCollection 2015.

20.

Comparison of the QMS Analyzer With HPLC-UV for the Quantification of Lamotrigine Concentrations in Human Plasma Samples.

Baldelli S, Castoldi S, Charbe N, Cozzi V, Fucile S, Cattaneo D, Clementi E.

Ther Drug Monit. 2015 Oct;37(5):689-94. doi: 10.1097/FTD.0000000000000202.

PMID:
25730145
21.

Is it time to revise antiretrovirals dosing? a pharmacokinetic viewpoint.

Cattaneo D, Baldelli S, Castoldi S, Charbe N, Cozzi V, Fucile S, Clementi E.

AIDS. 2014 Oct 23;28(16):2477-80.

PMID:
25392858
22.

Combined isosorbide dinitrate and ibuprofen as a novel therapy for muscular dystrophies: evidence from Phase I studies in healthy volunteers.

Cossu MV, Cattaneo D, Fucile S, Pellegrino P, Baldelli S, Cozzi V, Capetti A, Clementi E.

Drug Des Devel Ther. 2014 May 2;8:411-9. doi: 10.2147/DDDT.S58803. eCollection 2014.

23.

Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections.

Cattaneo D, Orlando G, Cozzi V, Cordier L, Baldelli S, Merli S, Fucile S, Gulisano C, Rizzardini G, Clementi E.

Int J Antimicrob Agents. 2013 Jun;41(6):586-9. doi: 10.1016/j.ijantimicag.2013.02.020. Epub 2013 Apr 4.

PMID:
23562639
24.

PTX3 as a potential endothelial dysfunction biomarker for severity of preeclampsia and IUGR.

Cozzi V, Garlanda C, Nebuloni M, Maina V, Martinelli A, Calabrese S, Cetin I.

Placenta. 2012 Dec;33(12):1039-44. doi: 10.1016/j.placenta.2012.09.009. Epub 2012 Oct 9.

PMID:
23062219
25.

Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing.

Cattaneo D, Baldelli S, Cerea M, Landonio S, Meraviglia P, Simioni E, Cozzi V, Fucile S, Gazzaniga A, Clementi E, Galli M, Rizzardini G, Gervasoni C.

Antimicrob Agents Chemother. 2012 Dec;56(12):6132-6. doi: 10.1128/AAC.00942-12. Epub 2012 Sep 10.

26.

Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects.

Cattaneo D, Gervasoni C, Meraviglia P, Landonio S, Fucile S, Cozzi V, Baldelli S, Pellegrini M, Galli M, Clementi E.

J Antimicrob Chemother. 2012 Feb;67(2):460-4. doi: 10.1093/jac/dkr498. Epub 2011 Nov 29.

PMID:
22127581
27.

Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients.

Cattaneo D, Ripamonti D, Baldelli S, Cozzi V, Fucile S, Clementi E.

Fundam Clin Pharmacol. 2013 Apr;27(2):216-22. doi: 10.1111/j.1472-8206.2011.01005.x. Epub 2011 Nov 2.

PMID:
22044510
28.

Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients.

Cattaneo D, Gervasoni C, Cozzi V, Baldelli S, Fucile S, Meraviglia P, Landonio S, Boreggio G, Rizzardini G, Clementi E.

Pharmacol Res. 2012 Feb;65(2):198-203. doi: 10.1016/j.phrs.2011.09.006. Epub 2011 Sep 20.

PMID:
21958880
29.

Estimation of fetal oxygen uptake in human term pregnancies.

Radaelli T, Boito S, Taricco E, Cozzi V, Cetin I.

J Matern Fetal Neonatal Med. 2012 Feb;25(2):174-9. doi: 10.3109/14767058.2011.566948. Epub 2011 Apr 7.

PMID:
21473676
30.

Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients.

Cattaneo D, Ripamonti D, Gervasoni C, Landonio S, Meraviglia P, Baldelli S, Cozzi V, Fucile S, Clementi E.

J Clin Pharmacol. 2012 Mar;52(3):440-5. doi: 10.1177/0091270010395939. Epub 2011 Mar 7.

PMID:
21383337
31.

Incomplete activation of peripheral blood dendritic cells during healthy human pregnancy.

Della Bella S, Giannelli S, Cozzi V, Signorelli V, Cappelletti M, Cetin I, Villa ML.

Clin Exp Immunol. 2011 May;164(2):180-92. doi: 10.1111/j.1365-2249.2011.04330.x. Epub 2011 Feb 24.

32.

Atypical pharmacokinetics of atazanavir in an HIV-1-infected patient.

Cattaneo D, Meraviglia P, Cozzi V, Baldelli S, Milani G, Clementi E.

Fundam Clin Pharmacol. 2012 Apr;26(2):204-6. doi: 10.1111/j.1472-8206.2010.00905.x. Epub 2011 Jan 7.

PMID:
21210843
33.

Virologic failure in an HIV-infected woman given desogestrel for excessive menstrual bleeding.

Cattaneo D, Meraviglia P, Beretta R, Baldelli S, Cozzi V, Milani G, Clementi E.

Eur J Clin Pharmacol. 2011 Apr;67(4):429-431. doi: 10.1007/s00228-010-0934-y. Epub 2010 Nov 3. No abstract available.

PMID:
21046092
34.

Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients.

Cattaneo D, Ripamonti D, Baldelli S, Cozzi V, Conti F, Clementi E.

Ther Drug Monit. 2010 Dec;32(6):782-6. doi: 10.1097/FTD.0b013e3181fa53b7.

PMID:
20926993
35.

Determination of linezolid in human plasma by high-performance liquid chromatography with ultraviolet detection.

Cattaneo D, Baldelli S, Conti F, Cozzi V, Clementi E.

Ther Drug Monit. 2010 Aug;32(4):520-4. doi: 10.1097/FTD.0b013e3181d5eeee.

PMID:
20300050
36.

First trimester PTX3 levels in women who subsequently develop preeclampsia and fetal growth restriction.

Cetin I, Cozzi V, Papageorghiou AT, Maina V, Montanelli A, Garlanda C, Thilaganathan B.

Acta Obstet Gynecol Scand. 2009;88(7):846-9. doi: 10.1080/00016340902971441.

37.

Maternal and fetal fatty acid profile in normal and intrauterine growth restriction pregnancies with and without preeclampsia.

Alvino G, Cozzi V, Radaelli T, Ortega H, Herrera E, Cetin I.

Pediatr Res. 2008 Dec;64(6):615-20. doi: 10.1203/PDR.0b013e31818702a2.

38.

Infertility as a cancer risk factor - a review.

Cetin I, Cozzi V, Antonazzo P.

Placenta. 2008 Oct;29 Suppl B:169-77. doi: 10.1016/j.placenta.2008.08.007. Review.

39.

Amino acids and mitochondrial biogenesis.

Nisoli E, Cozzi V, Carruba MO.

Am J Cardiol. 2008 Jun 2;101(11A):22E-25E. doi: 10.1016/j.amjcard.2008.02.077. Review.

PMID:
18514622
40.

Prediction of preeclampsia - a workshop report.

Than NG, Romero R, Hillermann R, Cozzi V, Nie G, Huppertz B.

Placenta. 2008 Mar;29 Suppl A:S83-5. Epub 2007 Dec 3.

41.

Placental IGF2 expression in normal and intrauterine growth restricted (IUGR) pregnancies.

Antonazzo P, Alvino G, Cozzi V, Grati FR, Tabano S, Sirchia S, Miozzo M, Cetin I.

Placenta. 2008 Jan;29(1):99-101. Epub 2007 Oct 24. No abstract available.

PMID:
17919721
42.

Maternal and foetal resistin and adiponectin concentrations in normal and complicated pregnancies.

Cortelazzi D, Corbetta S, Ronzoni S, Pelle F, Marconi A, Cozzi V, Cetin I, Cortelazzi R, Beck-Peccoz P, Spada A.

Clin Endocrinol (Oxf). 2007 Mar;66(3):447-53.

PMID:
17302882
43.

Intrauterine growth restriction is associated with alterations in placental lipoprotein receptors and maternal lipoprotein composition.

Wadsack C, Tabano S, Maier A, Hiden U, Alvino G, Cozzi V, Hüttinger M, Schneider WJ, Lang U, Cetin I, Desoye G.

Am J Physiol Endocrinol Metab. 2007 Feb;292(2):E476-84. Epub 2006 Sep 26.

44.

TNF-alpha downregulates eNOS expression and mitochondrial biogenesis in fat and muscle of obese rodents.

Valerio A, Cardile A, Cozzi V, Bracale R, Tedesco L, Pisconti A, Palomba L, Cantoni O, Clementi E, Moncada S, Carruba MO, Nisoli E.

J Clin Invest. 2006 Oct;116(10):2791-8. Epub 2006 Sep 14.

45.

White adipocytes are less prone to apoptotic stimuli than brown adipocytes in rodent.

Nisoli E, Cardile A, Bulbarelli A, Tedesco L, Bracale R, Cozzi V, Morroni M, Cinti S, Valerio A, Carruba MO.

Cell Death Differ. 2006 Dec;13(12):2154-6. Epub 2006 May 12. No abstract available.

46.

Elevated maternal levels of the long pentraxin 3 (PTX3) in preeclampsia and intrauterine growth restriction.

Cetin I, Cozzi V, Pasqualini F, Nebuloni M, Garlanda C, Vago L, Pardi G, Mantovani A.

Am J Obstet Gynecol. 2006 May;194(5):1347-53. Epub 2006 Apr 21.

PMID:
16647920
47.

Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS.

Nisoli E, Tonello C, Cardile A, Cozzi V, Bracale R, Tedesco L, Falcone S, Valerio A, Cantoni O, Clementi E, Moncada S, Carruba MO.

Science. 2005 Oct 14;310(5746):314-7.

48.

Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals.

Nisoli E, Falcone S, Tonello C, Cozzi V, Palomba L, Fiorani M, Pisconti A, Brunelli S, Cardile A, Francolini M, Cantoni O, Carruba MO, Moncada S, Clementi E.

Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16507-12. Epub 2004 Nov 15. Erratum in: Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5635.

49.

Lack of expression of endometrial prolactin in early implantation failure: a pilot study.

Garzia E, Borgato S, Cozzi V, Doi P, Bulfamante G, Persani L, Cetin I.

Hum Reprod. 2004 Aug;19(8):1911-6. Epub 2004 Jun 24.

PMID:
15218000
50.

Fetal development after assisted reproduction--a review.

Cetin I, Cozzi V, Antonazzo P.

Placenta. 2003 Oct;24 Suppl B:S104-13. Review.

PMID:
14559039

Supplemental Content

Support Center